Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 6/20 | 0.57 |
| ▸ | HCK | P08631 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326416 | 0.80 | LCK (0.50) | MAPTLMNATP53LCKHCK | |
| SCHEMBL6056741 | 0.78 | LCK (0.68) | LCKHCK | |
| SCHEMBL92336 | 0.76 | MEN1 (0.55) | MAPTTP53EPHX1 | |
| SCHEMBL16071443 | 0.75 | EPHX1 (0.76) | MAPTLMNATP53KDM4EEPHX1 | |
| SCHEMBL91601 | 0.74 | KDM4E (0.54) | MAPTLMNATP53LCKKDM4E | |
| SCHEMBL92220 | 0.74 | RAB9A (0.59) | MAPTTP53KDM4EEPHX1 | |
| SCHEMBL21283024 | 0.74 | LCK (1.00) | LCKHCK | |
| SCHEMBL6017856 | 0.74 | MCL1 (0.66) | MAPTTHRBGRM4 | |
| SCHEMBL6833093 | 0.72 | MCL1 (0.56) | MAPTLMNATP53GRM4 | |
| SCHEMBL12388794 | 0.72 | ALDH1A1 (0.83) | MAPTLMNAKDM4EEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-04-24 | — | — | US | disclosed |
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | MAPT 2650/4885LMNA 4433/4885TP53 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.